Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →TESERA: morphologic subtyping and prognostic stratification of hepatocellular carcinoma from H&E whole-slide images.
Clinical takeawayNo clinical action yet: a computational pathology tool validated in retrospective cohorts. Consider TESERA-MI for future risk stratification in HCC if validated prospectively.
What it foundTESERA-MI, a morphologic index derived from H&E whole-slide images, predicted overall survival (HR=3.17) and disease-free survival (HR=2.19) in HCC, outperforming clinical variables and molecular markers (C-index 0.73) in the TCGA-LIHC cohort and independently validated in an external cohort (HR=2.16).
ContextChallenges current reliance on clinical and molecular markers for HCC prognosis by demonstrating superior predictive power of routine histology-derived indices in HCC patients.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Yasaka TM … Chiu YC · Hepatology · IF 18.0 · PubMed ↗